Effects of test compounds on planktonic growth of P. aeruginosa clinical isolates
| Compounda . | Range (mg/L) . | MIC (mg/L) . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| susceptible isolates (n = 18)b . | resistant isolates (n = 14)b . | overall average (n = 32 isolates) . | ||||||||
| MIC50c . | MIC90c . | GM-MIC . | MIC50 . | MIC90 . | GM-MIC . | MIC50 . | MIC90 . | GM-MIC . | ||
| Phen | 50–200 | 100 | 200 | 108.01 | 100 | 200 | 105.08 | 100 | 200 | 106.71 (579.28 μM) |
| Phendione | 3.125–12.50 | 6.25 | 12.50 | 6.25 | 6.25 | 12.50 | 6.90 | 6.25 | 12.50 | 6.53 (31.15 μM) |
| [Ag(phendione)2]+ | 3.125–12.50 | 12.50 | 12.50 | 8.84 | 12.50 | 12.50 | 8.84 | 12.50 | 12.50 | 8.84 (14.05 μM) |
| [Cu(phendione)3]2+ | 3.125–12.50 | 6.25 | 12.50 | 7.58 | 6.25 | 12.50 | 7.25 | 6.25 | 12.50 | 7.43 (7.76 μM) |
| AgNO3 | 6.25–25 | 6.25 | 12.50 | 7.43 | 6.25 | 25 | 8.84 | 6.25 | 12.50 | 8.25 (48.54 μM) |
| CuSO4·5H2O | 6.25–200 | >200 | >200 | ND | >200 | >200 | ND | >200 | >200 | ND |
| Compounda . | Range (mg/L) . | MIC (mg/L) . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| susceptible isolates (n = 18)b . | resistant isolates (n = 14)b . | overall average (n = 32 isolates) . | ||||||||
| MIC50c . | MIC90c . | GM-MIC . | MIC50 . | MIC90 . | GM-MIC . | MIC50 . | MIC90 . | GM-MIC . | ||
| Phen | 50–200 | 100 | 200 | 108.01 | 100 | 200 | 105.08 | 100 | 200 | 106.71 (579.28 μM) |
| Phendione | 3.125–12.50 | 6.25 | 12.50 | 6.25 | 6.25 | 12.50 | 6.90 | 6.25 | 12.50 | 6.53 (31.15 μM) |
| [Ag(phendione)2]+ | 3.125–12.50 | 12.50 | 12.50 | 8.84 | 12.50 | 12.50 | 8.84 | 12.50 | 12.50 | 8.84 (14.05 μM) |
| [Cu(phendione)3]2+ | 3.125–12.50 | 6.25 | 12.50 | 7.58 | 6.25 | 12.50 | 7.25 | 6.25 | 12.50 | 7.43 (7.76 μM) |
| AgNO3 | 6.25–25 | 6.25 | 12.50 | 7.43 | 6.25 | 25 | 8.84 | 6.25 | 12.50 | 8.25 (48.54 μM) |
| CuSO4·5H2O | 6.25–200 | >200 | >200 | ND | >200 | >200 | ND | >200 | >200 | ND |
GM-MIC, geometric mean MIC; ND, not determined.
a[Ag(phendione)2]+ and [Cu(phendione)3]2+ represent [Ag(phendione)2]ClO4 and [Cu(phendione)3](ClO4)2·4H2O, respectively.
bAll the clinical strains of P. aeruginosa used in the present work were previously evaluated by disc-diffusion tests regarding their susceptibility profile to ceftazidime (30 mg/L), meropenem (10 mg/L) and imipenem (10 mg/L).13
cMIC50 and MIC90 correspond to the minimum concentrations of test compounds required to inhibit 50% and 90% of the clinical bacterial isolates, respectively.
Effects of test compounds on planktonic growth of P. aeruginosa clinical isolates
| Compounda . | Range (mg/L) . | MIC (mg/L) . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| susceptible isolates (n = 18)b . | resistant isolates (n = 14)b . | overall average (n = 32 isolates) . | ||||||||
| MIC50c . | MIC90c . | GM-MIC . | MIC50 . | MIC90 . | GM-MIC . | MIC50 . | MIC90 . | GM-MIC . | ||
| Phen | 50–200 | 100 | 200 | 108.01 | 100 | 200 | 105.08 | 100 | 200 | 106.71 (579.28 μM) |
| Phendione | 3.125–12.50 | 6.25 | 12.50 | 6.25 | 6.25 | 12.50 | 6.90 | 6.25 | 12.50 | 6.53 (31.15 μM) |
| [Ag(phendione)2]+ | 3.125–12.50 | 12.50 | 12.50 | 8.84 | 12.50 | 12.50 | 8.84 | 12.50 | 12.50 | 8.84 (14.05 μM) |
| [Cu(phendione)3]2+ | 3.125–12.50 | 6.25 | 12.50 | 7.58 | 6.25 | 12.50 | 7.25 | 6.25 | 12.50 | 7.43 (7.76 μM) |
| AgNO3 | 6.25–25 | 6.25 | 12.50 | 7.43 | 6.25 | 25 | 8.84 | 6.25 | 12.50 | 8.25 (48.54 μM) |
| CuSO4·5H2O | 6.25–200 | >200 | >200 | ND | >200 | >200 | ND | >200 | >200 | ND |
| Compounda . | Range (mg/L) . | MIC (mg/L) . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| susceptible isolates (n = 18)b . | resistant isolates (n = 14)b . | overall average (n = 32 isolates) . | ||||||||
| MIC50c . | MIC90c . | GM-MIC . | MIC50 . | MIC90 . | GM-MIC . | MIC50 . | MIC90 . | GM-MIC . | ||
| Phen | 50–200 | 100 | 200 | 108.01 | 100 | 200 | 105.08 | 100 | 200 | 106.71 (579.28 μM) |
| Phendione | 3.125–12.50 | 6.25 | 12.50 | 6.25 | 6.25 | 12.50 | 6.90 | 6.25 | 12.50 | 6.53 (31.15 μM) |
| [Ag(phendione)2]+ | 3.125–12.50 | 12.50 | 12.50 | 8.84 | 12.50 | 12.50 | 8.84 | 12.50 | 12.50 | 8.84 (14.05 μM) |
| [Cu(phendione)3]2+ | 3.125–12.50 | 6.25 | 12.50 | 7.58 | 6.25 | 12.50 | 7.25 | 6.25 | 12.50 | 7.43 (7.76 μM) |
| AgNO3 | 6.25–25 | 6.25 | 12.50 | 7.43 | 6.25 | 25 | 8.84 | 6.25 | 12.50 | 8.25 (48.54 μM) |
| CuSO4·5H2O | 6.25–200 | >200 | >200 | ND | >200 | >200 | ND | >200 | >200 | ND |
GM-MIC, geometric mean MIC; ND, not determined.
a[Ag(phendione)2]+ and [Cu(phendione)3]2+ represent [Ag(phendione)2]ClO4 and [Cu(phendione)3](ClO4)2·4H2O, respectively.
bAll the clinical strains of P. aeruginosa used in the present work were previously evaluated by disc-diffusion tests regarding their susceptibility profile to ceftazidime (30 mg/L), meropenem (10 mg/L) and imipenem (10 mg/L).13
cMIC50 and MIC90 correspond to the minimum concentrations of test compounds required to inhibit 50% and 90% of the clinical bacterial isolates, respectively.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
